Neutral Dr. Reddy's Laboratories Ltd. at a price target of Rs 2890. orecast EBITDA margins of 23% in FY18, up 470bps YoY. Expect sales grow...

The Sun Pharma stock is down 44% from its record high of Rs 1,200 hit in April 2015. There is limited room for the stock price to sustain a...

The global investment bank is of the view that the stock is fully priced for 2 year forward earnings per share (EPS).

Management guided 8-10% sales growth and EBITDA margin will be impacted with higher R&D costs of above 8% of sales,"

Consolidated revenues for the quarter grew 21% — thanks to the two months of exclusivity period sales of generic drug Gleevec.

Drug maker Sun Pharmaceuticals launched Imatinib Mesylate, the generic copy of anti-cancer drug Gleevec, in the US market enjoying 180 days...

There has been a lot of PE money which has gone in building five-star multi-speciality hospital assets in these tier 2, tier 3 cities, says...

Even without the Gleevec approval, we were estimating a 9.3% top line growth for Su Pharma for the next two years, says Joshi.

Brokering houses remained positive on the stock, with CLSA and Bank of America-Meryll Lynch (BofA ML) maintaining buy ratings on the scrip.

SurajitPal, analyst at Prabhudas Lilladher factored in the best-case scenario putting Sun Pharma’s sales from Gleevec at $450 million.

Sun Pharmaceutical announced it received approval from the US FDA for generic copies of Gleevec, a drug that treats chronic myeloid leukemi...

In reaction to the development, the scrip surged 6.46 per cent to hit day's high of Rs 773 on the BSE. The volumes were at three times the ...

Sun Pharmaceutical Industries Ltd said it was allowed to launch a generic version of Novartis' leukemia drug Gleevec in the US

India is likely to drag the US to WTO if America includes it in the 'Priority Foreign Country' list for intellectual property rights.

Patent applications filed by Indian pharma firms have witnessed a sharp fall of 41% during FY08.

The final hearings on the Novartis petition challenging the clause of the Indian Patent Act Amendment (2005), which does not accord patents...

Gleevec, the pill that offered an easy way to target a difficult type of leukemia, may cause serious heart damage, researchers cautioned.